Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase
- PMID: 631898
- DOI: 10.1007/BF01641085
Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase
Abstract
2% amphotericin B in orabase was applied to the buccal mucous membranes of healthy volunteers. Amounts of 1 g and 0.5 g were used. The experiments were performed during the day time as well as during the sleeping hours at night. At several intervals after application saliva samples were collected and the amphotericin B concentrations were determined. Application of 1 g of orabase with 2% amphotericin B appears to maintain a sufficiently high concentration for four hours, 0.5 g for three hours. Application of these amounts before going to sleep guarantees a sufficient concentration until awakening the next morning.
Similar articles
-
Salivary concentrations of amphotericin B following its use as an oral lozenge.Infection. 1980;8(2):63-5. doi: 10.1007/BF01639148. Infection. 1980. PMID: 6993365
-
Absorption of orally administered amphotericin B lozenges.Br J Clin Pharmacol. 1983 Jul;16(1):106-8. doi: 10.1111/j.1365-2125.1983.tb02152.x. Br J Clin Pharmacol. 1983. PMID: 6882617 Free PMC article.
-
Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses.Infection. 1982;10(4):223-7. doi: 10.1007/BF01666915. Infection. 1982. PMID: 7129644
-
Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections?Ann Pharmacother. 1996 Jul-Aug;30(7-8):811-8. doi: 10.1177/106002809603000720. Ann Pharmacother. 1996. PMID: 8826566 Review.
-
Amphotericin B toxicity reduced by administration in fat emulsion.Ann Pharmacother. 1995 May;29(5):496-500. doi: 10.1177/106002809502900509. Ann Pharmacother. 1995. PMID: 7655134 Review.
Cited by
-
E.O.R.T.C. Gnotobiotic Project Group: a prospective cooperative study of antimicrobial decontamination in granulocytopenic patients. Comparison of two different methods.Infection. 1982;10(3):131-8. doi: 10.1007/BF01640762. Infection. 1982. PMID: 7049955 Clinical Trial.
-
Salivary concentrations of amphotericin B following its use as an oral lozenge.Infection. 1980;8(2):63-5. doi: 10.1007/BF01639148. Infection. 1980. PMID: 6993365
-
The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients.Infection. 1982;10(2):71-5. doi: 10.1007/BF01816727. Infection. 1982. PMID: 6954128
-
Clinical use of selective decontamination: the concept.Intensive Care Med. 1990;16 Suppl 3:S212-6. doi: 10.1007/BF01709703. Intensive Care Med. 1990. PMID: 2289993